LPCN Lipocine Inc.

1.39
+0.01  (+1%)
Previous Close 1.38
Open 1.37
Price To Book 2.53
Market Cap 29835002
Shares 21,464,030
Volume 27,498
Short Ratio
Av. Daily Volume 93,184

SEC filingsSee all SEC filings

  1. 8-K - Current report 181173020
  2. 8-K - Current report 181168224
  3. 8-K - Current report 181164769
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181164764
  5. 8-K - Current report 181158779

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. End of Phase 2b meeting with FDA planned 1Q 2018.
LPCN 1111
Oral testosterone product
CRL issued June 2016. Further CRL issued May 9, 2018. Data from ambulatory blood pressure trial due 1Q 2019.
LPCN 1021
Men with low testosterone (Low T)
Conduct food/fact effect study 2H 2018 in preparation for Phase 3 trial.
LPCN 1107
Prevention of preterm birth ("PTB").
Data due 1Q 2019.
LPCN 1144
Liver Imaging Study in Subjects At-Risk for NASH

Latest News

  1. LPCN: Tlando Readouts Coming Soon; NDA to Follow
  2. Lipocine Inc (NASDAQ:LPCN): Are Analysts Optimistic?
  3. Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth
  4. Lipocine: 3Q Earnings Snapshot
  5. Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018
  6. Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH
  7. Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO™
  8. LPCN: Androgen Therapy in NASH: A Comprehensive Approach
  9. Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018
  10. Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference
  11. Do Institutions Own Shares In Lipocine Inc (NASDAQ:LPCN)?
  12. LPCN: 2Q:18 Operational and Financial Results
  13. Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018
  14. Lipocine to Present at the Canaccord Genuity 38th Annual Growth Conference
  15. Free Research Reports on Ironwood Pharma and Three More Generic Drugs Stocks
  16. Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO™
  17. Analysts Expect Breakeven For Lipocine Inc (NASDAQ:LPCN)
  18. LPCN: Another CRL: Updated Timeline Points to 1Q:19 FDA Response
  19. Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks

SEC Filings

  1. 8-K - Current report 181173020
  2. 8-K - Current report 181168224
  3. 8-K - Current report 181164769
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181164764
  5. 8-K - Current report 181158779
  6. 8-K - Current report 181153629
  7. 8-K - Current report 181117288
  8. 8-K - Current report 181095906
  9. 424B5 - Prospectus [Rule 424(b)(5)] 181079604
  10. 8-K - Current report 181042953